Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253950 | 0.82 | NQO1 (0.47) | MAPTALDH1A1KDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL8125064 | 0.82 | LTA4H (0.46) | MAPTALDH1A1KDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL2502508 | 0.80 | MAPT (0.34) | MAPTALDH1A1KDM4ESMN1; SMN2CYP2A6 | |
| SCHEMBL2498961 | 0.80 | MAPT (0.34) | MAPTALDH1A1KDM4ECYP2A6TSHR | |
| SCHEMBL2505168 | 0.79 | ALDH1A1 (0.37) | MAPTALDH1A1KDM4ECYP2A6TSHR | |
| SCHEMBL1452144 | 0.79 | ALOX5 (0.37) | ALDH1A1KDM4ECYP2A6TSHRHSD17B10 | |
| SCHEMBL15232707 | 0.79 | CYP2A6 (0.34) | MAPTALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL8492149 | 0.79 | CYP2A6 (0.34) | MAPTALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL2504735 | 0.79 | MAPT (0.42) | MAPTALDH1A1KDM4ECYP2A6TSHR | |
| SCHEMBL2498963 | 0.78 | KDM1A (0.39) | MAPTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110092788-B | Substituted [1,2,4] triazolo [1,5-a ] pyrimidin-7-yl compounds as PDE2 inhibitors | 达特神经科学(开曼)有限公司 | 2022-02-25 | — | — | CN | claimed |
| EP-3597649-B1 | COMPOSITIONS CONTAINING SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| EP-3134413-B1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-09-11 | — | — | EP | claimed |
| US-9932345-B2 | Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-04-03 | — | — | US | claimed |
| US-9834537-B2 | Compounds as chloride channel blocking agent | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-12-05 | — | — | US | claimed |
| US-20170057967-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2017-03-02 | — | — | US | claimed |
| EP-3134413-A1 | SUBSTITUTED [1,2,4]TRIAZOLO [1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2017-03-01 | — | — | EP | claimed |
| US-9296738-B2 | Organic electroluminescent material, the process for preparing the same and OLED device using the same | EVERDISPLAY OPTRONICS (SHANGHAI) LIMITED (CN) | 2016-03-29 | — | — | US | claimed |
| WO-2015164508-A1 | SUBSTITUTED [1,2,4] TRIAZOLO [1,5-A] PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2015-10-29 | — | — | WO | claimed |
| EP-1778639-B1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RES INC (US) | 2015-09-02 | — | — | EP | claimed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | CURIA GLOBAL, INC. | 2006-03-09 | — | — | US | claimed |
| WO-2006020049-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | claimed |
| US-5821024-A | POLYESTER BINDER OF A DICARBOXYLIC ACID AND A POLYOL BLEND OF ETHERIFIED DIPHENOLS | EASTMAN KODAK COMPANY (US) | 1998-10-13 | — | — | US | claimed |
| EP-0132854-B1 | PROCESS FOR THE OPTICAL RESOLUTION OF (+/-) 2-(6'-METHOXY-2'-NAPHTHYL)-PROPIONIC ACIDS | Nobel Chemicals AB (SE) | 1987-08-05 | — | — | EP | claimed |
| US-4276375-A | CONTACTING WITH CHROMOGENIC OR FLUOROGENIC SUBSTRATE, SPECTROPHOTOMETRY | AB KABI (SE) | 1981-06-30 | — | — | US | claimed |
| US-4207232-A | FOR SERINE PROTEASES | AB KABI (SE) | 1980-06-10 | — | — | US | claimed |
| US-4066758-A | ANTITHROMBOTIC | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052378-A1 | Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride | OPRK1, OPRL1, OPRD1 | MAPT 2461/4885ALDH1A1 777/4885KDM4E 759/4885 |
| US-20170057967-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, TDP2 | MAPT 774/4885ALDH1A1 1555/4885KDM4E 3053/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | MAPT 744/4885ALDH1A1 1331/4885KDM4E 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.